Nicholas Jette, Adam Fundytus and Jose Monson
Abstract
Pancreatic cancer remains a difficult to treat malignancy. Advanced application of targeted chemotherapeutics has extended survival but has not resulted in cure. Recently, the application of immunotherapy has shown promise in cancers that harbour mismatch repair deficiencies and micro-satellite instability. Here, we show a metastatic pancreatic cancer with a mismatch repair deficiency respond dramatically to PD-1 inhibitor therapy.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi